| Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma A Orillion, A Hashimoto, N Damayanti, L Shen, R Adelaiye-Ogala, S Arisa, ... Clinical cancer research 23 (17), 5187-5201, 2017 | 336 | 2017 |
| Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer L Fontana, RM Adelaiye, AL Rastelli, KM Miles, E Ciamporcero, ... Oncotarget 4 (12), 2451, 2013 | 149 | 2013 |
| YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage E Ciamporcero, H Shen, S Ramakrishnan, S Yu Ku, S Chintala, L Shen, ... Oncogene 35 (12), 1541-1553, 2016 | 126 | 2016 |
| Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models E Ciamporcero, KM Miles, R Adelaiye, S Ramakrishnan, L Shen, SY Ku, ... Molecular cancer therapeutics 14 (1), 101-110, 2015 | 109 | 2015 |
| Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models L Shen, A Sundstedt, M Ciesielski, KM Miles, M Celander, R Adelaiye, ... Cancer immunology research 3 (2), 136-148, 2015 | 100 | 2015 |
| Dietary protein restriction reprograms tumor-associated macrophages and enhances immunotherapy A Orillion, NP Damayanti, L Shen, R Adelaiye-Ogala, H Affronti, ... Clinical Cancer Research 24 (24), 6383-6395, 2018 | 86 | 2018 |
| Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial R Pili, G Liu, S Chintala, H Verheul, S Rehman, K Attwood, MA Lodge, ... British journal of cancer 116 (7), 874-883, 2017 | 83 | 2017 |
| EZH2 modifies sunitinib resistance in renal cell carcinoma by kinome reprogramming R Adelaiye-Ogala, J Budka, NP Damayanti, J Arrington, M Ferris, CC Hsu, ... Cancer research 77 (23), 6651-6666, 2017 | 73 | 2017 |
| Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications R Adelaiye, E Ciamporcero, KM Miles, P Sotomayor, J Bard, M Tsompana, ... Molecular cancer therapeutics 14 (2), 513-522, 2015 | 71 | 2015 |
| Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma NP Damayanti, JA Budka, HWZ Khella, MW Ferris, SY Ku, E Kauffman, ... Clinical Cancer Research 24 (23), 5977-5989, 2018 | 70 | 2018 |
| Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts KM Miles, M Seshadri, E Ciamporcero, R Adelaiye, B Gillard, ... PloS one 9 (11), e112371, 2014 | 66 | 2014 |
| Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor R Adelaiye-Ogala, BE Gryder, YTM Nguyen, AN Alilin, AR Grayson, ... Molecular cancer therapeutics 19 (7), 1436-1447, 2020 | 42 | 2020 |
| Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor … KJ Gotink, HJ Broxterman, RJ Honeywell, H Dekker, RR de Haas, ... Oncoscience 1 (12), 844, 2014 | 32 | 2014 |
| Development of a castrate resistant transplant tumor model of prostate cancer L Ellis, K Lehet, S Ramakrishnan, R Adelaiye, R Pili The Prostate 72 (6), 587-591, 2012 | 31 | 2012 |
| Therapeutic targeting of sunitinib-induced AR phosphorylation in renal cell carcinoma R Adelaiye-Ogala, NP Damayanti, AR Orillion, S Arisa, S Chintala, ... Cancer research 78 (11), 2886-2896, 2018 | 28 | 2018 |
| Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression L Ellis, K Lehet, S Ramakrishnan, R Adelaiye, KM Miles, D Wang, S Liu, ... PloS one 6 (11), e27178, 2011 | 23 | 2011 |
| Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer SY Ku, E Lasorsa, R Adelaiye, S Ramakrishnan, L Ellis, R Pili PLoS One 9 (7), e103680, 2014 | 18 | 2014 |
| Phase I study of dalteparin in combination with sunitinib in patients with metastatic clear cell renal carcinoma MQ Wentink, HMW Verheul, SK Pal, S George, J Voortman, ... Clinical Genitourinary Cancer 16 (1), e1-e9, 2018 | 11 | 2018 |
| Dual inhibition of angiopoietin-TIE2 and MET alters the tumor microenvironment and prolongs survival in a metastatic model of renal cell carcinoma M Elbanna, AR Orillion, NP Damayanti, R Adelaiye-Ogala, L Shen, ... Molecular cancer therapeutics 19 (1), 147-156, 2020 | 10 | 2020 |
| Overcoming sunitinib-induced resistance by dose escalation in renal cell carcinoma: Evidence in animal models and patients. R Pili, R Adelaiye, KM Miles, E Ciamporcero, P Sotomayor, GA Bjarnason Journal of clinical oncology 31 (15_suppl), 4582-4582, 2013 | 7 | 2013 |
